Prescribing Information for ▼PAXLOVID (nirmatrelvir / ritonavir) can be found here: Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page. Please note, there are differences between the SmPC for Northern Ireland and the SmPC for Great Britain. Please refer to the appropriate SmPC depending on where you are based.
Paxlovid has a Conditional Marketing Authorisation in Great Britain. A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.
Watch short educational key-opinion-leader (KOL) videos from Healthcare Professionals on their experience in discussing the importance of identifying and managing patients at risk of severe COVID-19.
Intended for UK HCPs:
Prof Mark Nelson, Professor of HIV Medicine, Chelsea and Westminster Hospital, London, UK
Prof Nelson reviews the impact COVID-19 is still having on the NHS and the groups of patients who are most at risk of developing severe COVID-19.
Paxlovid GB Prescribing Information
Paxlovid NI Prescribing Information
PP-PAX-GBR-0621. May 2023.
6 mins, 20 secs
Intended for GB HCPs:
Dr Faheem Shakur, General Practitioner, Stonyhill Medical Practice, Blackpool, UK
Dr Shakur discusses the approach at his surgery to identifying and educating patients at high-risk of severe COVID-19 progession with a focus on reducing health inequalities.
Comirnaty®▼(tozinameran) COVID-19 mRNA Vaccine (nucleoside modified) Prescribing Information
Paxlovid GB Prescribing Information
PP-PAX-GBR-0622. May 2023.
5 mins, 25 secs
Intended for UK HCPs:
Prof David Strain, Associate Professor in Cardiometabolic Health, University of Exeter Medical School
Prof Strain discusses the key aspects needed for an effective COVID-19 treatment service, highlighting important considerations and best practice which others can use to help optimise their own pathways.
Paxlovid GB Prescribing Information
Paxlovid NI Prescribing Information
PP-PAX-GBR-0624. July 2023.
6 mins, 42 secs
Navigate to the Paxlovid Educational Resources page to download materials available to support both you and your Paxlovid patients.
Adverse Events
Adverse Events should be reported. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024